-
31.发明授权THERAPEUTIC EFFECTS OF BRYOSTATINS, BRYOLOGS, AND OTHER RELATED SUBSTANCES ON HEAD TRAUMA-INDUCED MEMORY IMPAIRMENT AND BRAIN INJURY 有权BY创伤病苔藓抑素，BRYOLOGEN及其他相关物质头部的治疗作用实现的内存问题及脑损伤
公开(公告)号：EP2121000B1
公开(公告)日：2015-09-23
申请号：EP08725395.1
申请日：2008-02-11
发明人： ZOHAR, Ofer , ALKON, Daniel, L.
IPC分类号： A61K31/00 , A61K31/05 , A61K31/335 , A61K31/35 , A61K31/365 , A61K31/395 , A61K31/4015 , A61K38/00 , A61K38/18
CPC分类号： A61K38/1825 , A61K31/00 , A61K31/05 , A61K31/335 , A61K31/35 , A61K31/365 , A61K31/395 , A61K31/4015 , A61K38/00
摘要： The invention provides for the use of protein kinase activators or boosters of nerve growth factor (NGF), brainderived neurotrophic factor (BDNF) or other neurotrophic factors to treat head trauma. Specifically, the present invention provides methods of treating head trauma comprising the steps of identifying a subject having suffered a head trauma and administering to said subject an amount of a pharmaceutical composition comprising a protein kinase C (PKC) activator or 4-methylcatechol acetic acid (MCBA) and a pharmaceutically acceptable carrier effective to treat at least one symptom of head trauma.
-
公开(公告)号：EP2776018A1
公开(公告)日：2014-09-17
申请号：EP12794822.2
申请日：2012-11-13
IPC分类号： A61K31/045 , A61K31/07 , A61K31/19 , A61K31/191 , A61K31/20 , A61K31/201 , A61K31/202 , A61K31/203 , A61K31/215 , A61K31/23 , A61K31/231 , A61K31/232 , A61K31/365 , A61P25/00
CPC分类号： A61K9/1275 , A61K31/203 , A61K31/215 , A61K31/231 , A61K31/365 , G01N33/5058
摘要： The present disclosure relates to PKC activators and combinations thereof. The disclosure further relates to compositions, kits, uses, and methods thereof.
摘要翻译： 本公开涉及PKC激活剂及其组合。 本公开还涉及组合物，试剂盒，用途及其方法。
-
33.发明公开Methods of stimulating cellular growth, synaptic remodeling and consolidation of long-term memory 审中-公开一种用于刺激细胞生长，突触形成和长期记忆的固化方法
公开(公告)号：EP2762136A1
公开(公告)日：2014-08-06
申请号：EP14001452.3
申请日：2007-01-29
IPC分类号： A61K31/365 , A61P25/28
CPC分类号： A61K31/366 , A61K31/365 , A61K31/407 , A61K45/06 , A61K2300/00
摘要： The present invention provides methods of slowing or reversing the loss of memory and learning comprising the steps of contacting an effective amount of a PKC activator with a protein kinase C (PKC) in a subject identified with memory loss slowing or reversing memory loss. The present invention provides methods of stimulating cellular growth, neuronal growth, dendritic growth, dendritic spine formation, dendritic spine density, and the translocation of ELAV to proximal dendrites, and synaptic remodeling. The present invention also provides methods of contacting a protein kinase C (PKC) activator with a PKC activator in a manner sufficient to stimulate the synthesis of proteins sufficient to consolidate long-term memory. The present invention also provides methods of contacting a protein kinase C (PKC) activator with a PKC activator in a manner sufficient to downregulate PKC.
摘要翻译： 本发明提供了减缓或逆转记忆丧失的学习和包含有效量的与记忆丧失减缓或逆转记忆丧失鉴定受试者中的蛋白激酶C（PKC）PKC激活剂的接触的步骤的方法。 本发明提供了刺激细胞生长，神经元生长，枝晶生长，树突书脊形成，树突棘密度，和ELAV的近端树突易位，和突触重建的方法。 本发明因此提供接触蛋白激酶C（PKC）活化剂与在足以刺激足够的巩固长期记忆蛋白的合成的方式PKC激活剂的方法。 本发明因此提供接触蛋白激酶C（PKC）活化剂以足以下调PKC的方式PKC激活剂的方法。
-
34.发明授权
公开(公告)号：EP2317321B1
公开(公告)日：2014-04-02
申请号：EP10012836.2
申请日：2006-09-25
发明人： Khan, Tapan, Kumar , Alkon, Daniel
CPC分类号： G01N33/6896 , G01N33/5008 , G01N33/502 , G01N33/5091 , G01N2333/4709 , G01N2333/912 , G01N2800/2821
摘要： The present invention relates to methods of diagnosing Alzheimer's Disease as well as to methods of confirming the presence or absence of Alzheimer's Disease in a subject. The present invention is also directed to methods of identifying a lead compound useful for the treatment of Alzheimer's Disease by contacting non-Alzheimer's cells with an amyloid beta peptide, stimulating the cells with a protein kinase C activator, contacting the cells with a test compound, and determining the value of an Alzheimer's Disease-specific molecular biomarker. The present invention is also directed to methods of diagnosing Alzheimer's Disease in a subject by detecting alterations in the ratio of specific phosphorylated MAP kinase proteins in cells after stimulation with a protein kinase C activator. The Alzheimer's Disease-specific molecular biomarkers disclosed herein are useful for the diagnosis of Alzheimer's Disease, monitoring the progression of Alzheimer's Disease in a subject and in screening methods for the identification of compounds for treating or preventing Alzheimer's Disease. The invention is also directed to kits containing reagents for the detection and diagnosis of the presence or absence of Alzheimer's Disease using the Alzheimer's Disease-specific molecular biomarkers disclosed herein.
-
35.发明授权Alzheimer's disease-specific alterations of the ERK1/ERK2 phosphorylation ratio as Alzheimer's disease-specific molecular biomarkers (ADSMB) 有权阿尔茨海默氏病的ERK1的具体变化/ ERK2Phosphorylierungsverhältnisses阿尔茨海默氏疾病特异性分子标志物（ADSMB）
公开(公告)号：EP2031398B1
公开(公告)日：2013-02-13
申请号：EP08020258.3
申请日：2006-09-25
CPC分类号： G01N33/6896 , G01N33/5008 , G01N33/502 , G01N33/5091 , G01N2333/4709 , G01N2333/912 , G01N2800/2821
摘要： The present invention relates to methods of diagnosing Alzheimer's Disease as well as to methods of confirming the presence or absence of Alzheimer's Disease in a subject. The present invention is also directed to methods of identifying a lead compound useful for the treatment of Alzheimer's Disease by contacting non-Alzheimer's cells with an amyloid beta peptide, stimulating the cells with a protein kinase C activator, contacting the cells with a test compound, and determining the value of an Alzheimer's Disease-specific molecular biomarker. The present invention is also directed to methods of diagnosing Alzheimer's Disease in a subject by detecting alterations in the ratio of specific phosphorylated MAP kinase proteins in cells after stimulation with a protein kinase C activator. The Alzheimer's Disease-specific molecular biomarkers disclosed herein are useful for the diagnosis of Alzheimer's Disease, monitoring the progression of Alzheimer's Disease in a subject and in screening methods for the identification of compounds for treating or preventing Alzheimer's Disease. The invention is also directed to kits containing reagents for the detection and diagnosis of the presence or absence of Alzheimer's Disease using the Alzheimer's Disease-specific molecular biomarkers disclosed herein.
-
公开(公告)号：EP1961447B1
公开(公告)日：2012-10-24
申请号：EP08010738.6
申请日：2005-05-18
发明人： Sun, Miao-Kun , Alkon, David L.
IPC分类号： A61P25/24 , A61K31/365 , A61K31/192 , A61K31/196 , A61K31/045 , A61K31/05 , A61K31/4164 , A61K31/4172
CPC分类号： A61K38/1825 , A61K31/045 , A61K31/05 , A61K31/192 , A61K31/196 , A61K31/365 , A61K31/366 , A61K31/4164 , A61K31/4172
摘要： The invention provides for the use of protein kinase C activators to treat depressive disorders.
-
37.发明公开
公开(公告)号：EP2326729A1
公开(公告)日：2011-06-01
申请号：EP09790876.8
申请日：2009-07-28
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2600/136 , C12Q2600/158 , G01N2800/2821
摘要： The present invention relates to a method for diagnosing Alzheimer's Disease (AD) using PKC-elicited gene expression profiles. PKC-activation elicits different genomic profiles in AD cells, as compared with control cells, which can be used to diagnose AD and individuals at risk for developing AD.
-
38.发明公开ALZHEIMER'S DISEASE-SPECIFIC ALTERATIONS OF THE ERK1/ERK2 PHOSPHORYLATION RATIO-ALZHEIMER'S DISEASE-SPECIFIC MOLECULAR BIOMARKERS (ADSMB) 审中-公开在ERK1 / ERK2PHOSPHORYLIERUNGSVERHÄLTNISSES克罗恩阿尔茨海默病特异性改变阿尔茨海默氏病特有的分子标志物
公开(公告)号：EP2263090A1
公开(公告)日：2010-12-22
申请号：EP09731007.2
申请日：2009-04-03
IPC分类号： G01N33/68
CPC分类号： G01N33/6896 , G01N2800/2821 , G01N2800/52
摘要： The present invention relates to methods of diagnosing Alzheimer's Disease as well as to methods of confirming the presence or absence of Alzheimer's Disease in a subject. The present invention is also directed to methods of identifying a lead compound useful for the treatment of Alzheimer's Disease by contacting non-Alzheimer's cells with an amyloid beta peptide, stimulating the cells with a protein kinase C activator, contacting the cells with a test compound, and determining the value of an Alzheimer's Disease-specific molecular biomarker. The present invention is also directed to methods of diagnosing Alzheimer's Disease in a subject by detecting alterations in the ratio of specific phosphorylated MAP kinase proteins in cells after stimulation with a protein kinase C activator. The Alzheimer's Disease- specific molecular biomarkers disclosed herein are useful for the diagnosis of Alzheimer's Disease, monitoring the progression of Alzheimer's Disease in a subject and in screening methods for the identification of compounds for treating or preventing Alzheimer's Disease. The invention is also directed to kits containing reagents for the detection and diagnosis of the presence or absence of Alzheimer's Disease using the Alzheimer's Disease-specific molecular biomarkers disclosed herein.
-
公开(公告)号：EP1935414A2
公开(公告)日：2008-06-25
申请号：EP08003718.7
申请日：2002-05-02
发明人： Alkon, Daniel , Sun, Miao-Kun
IPC分类号： A61K31/137 , A61K31/198 , A61K31/4164 , A61K31/4178 , A61K31/417 , A61K31/4172 , A61P25/28
CPC分类号： A61K31/137 , A61K31/198 , A61K31/4164 , A61K31/417 , A61K31/4172 , A61K31/4178
摘要： The invention provides activator compounds for improving attentive cognition comprising administering a compound that potentiates intraneuronal carbonic anhydrase activity thereby improving establishment of a theta rhythm.
摘要翻译： 本发明提供用于改善认知周到包括给予的化合物确实potentiates元内碳酸酐酶活性从而改善建立θ节律的活化剂化合物。
-
40.发明公开USE OF A PKC ACTIVATOR, ALONE OR COMBINED WITH A PKC INHIBITOR TO ENHANCE LONG TERM MEMORY 审中-公开PKC激活剂，单独使用或与甲PKC抑制剂联合的用途，以提高长期记忆
公开(公告)号：EP1915145A1
公开(公告)日：2008-04-30
申请号：EP06788613.5
申请日：2006-07-28
发明人： ALKON, Daniel, L.
IPC分类号： A61K31/366 , A61K31/4015 , A61P25/28
CPC分类号： A61K31/366 , A61K31/365 , A61K31/40 , A61K31/4015 , A61K31/407 , A61K31/437
摘要： The present invention provides methods of contacting a protein kinase C (PKC) activator with a PKC activator in a manner sufficient to stimulate the synthesis of proteins sufficient to consolidate long-term memory. The present invention also provides methods of contacting a protein kinase C (PKC) activator with a PKC activator in a manner sufficient to downregulate PKC.
-
-
-
-
-
-
-
-
-
搜索结果
81 条记录 (耗时 0.033 秒)
